HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Suárez, C Articles by Becu-Villalobos, D Search for Related Content PubMed PubMed Citation Articles by Suárez, C Articles by Becu-Villalobos, D

Instituto de Biología y Medicina Experimental, CONICET, V, Obligado 2490, Buenos Aires 1428, Argentina

(Requests for offprints should be addressed to D Becu-Villalobos; Email: dbecu{at}dna.uba.ar)

In view of the present controversy related to the potential beneficial effects of clinical dehydroepiandrosterone (DHEA) treatments, and considering our own previous results that reveal an influence of this steroid in pituitary hyperplasia development in vivo in rats, we decided to evaluate the role of DHEA in prolactin and GH secretion, as well as in second messengers involved, in cultured rat anterior pituitary cells. DHEA (1 x 10^–5 to 1 x 10^–7 M) did not modify basal GH or prolactin release, and a prolactin inhibitory effect was observed only for androstenediol, a metabolite of DHEA. DHEA partially prevented dopamine (1 x 10^–6 M)-induced prolactin inhibition and facilitated the prolactin-releasing effect of 10^–8 M Ang II, without modifying the resulting Ca²⁺_i mobilization. Furthermore, DHEA potentiated the GH release and cAMP production induced by 1 x 10^–8 M GHRH. Finally, DHEA partially reversed the inhibitory effect of 1 x 10^–8 M somatostatin on GH, but not prolactin, release. We conclude that DHEA in vitro, directly or indirectly through conversion into metabolites, is able to modulate the hormonal response of the pituitary to hypothalamic regulators. It can enhance pituitary prolactin release and induce GH secretion. These effects could help explain some of the side effects observed in prolonged DHEA treatments in vivo and should be taken into account when considering its use in human clinical trials.

This article has been cited by other articles:

				M. Iruthayanathan, Y.-H. Zhou, and G. V. Childs Dehydroepiandrosterone Restoration of Growth Hormone Gene Expression in Aging Female Rats, in Vivo and in Vitro: Evidence for Actions via Estrogen Receptors Endocrinology, December 1, 2005; 146(12): 5176 - 5187. [Abstract] [Full Text] [PDF]